AURORA SPINE CORP - ASAPF STOCK NEWS

Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has launched its new OSTEO ONYX™ lumbar fusion system, featuring Rough Surface Technology (RST). This innovative system is designed to accommodate both standard spine patients and those with challenging conditions such as osteopenia or osteoporosis.

Ron Eckels, US Director of Spine at Aurora Spine, highlighted the system's versatility in treating a wide range of patients. Dr. Daniel Barba of San Diego, CA, was the first surgeon to use the Hydra Osteo Onyx MIS System in the United States. He praised the roughened surface technology for providing excellent purchase within the pedicle, benefiting patients with osteoporosis or poor bone quality. Dr. Barba also noted that the range of MIS screws (4.5mm to 10.5mm) allows for minimally invasive procedures, leading to improved patient recovery and satisfaction.

Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced its participation in the 2024 North American Spine Society (NASS) Annual Meeting from September 25-28, 2024, at McCormick Place, Chicago. The company will showcase its latest innovations at Booth #4510, including:

• SiLO™ TFX SI Fusion System for sacroiliac joint fusion surgery
• DEXA-C cervical interbody cage system with patented DEXA™ Technology
• Hydra™ and OSTEO-ONYX™ lumbar fusion systems with Rough Surface Technology (RST)
• ZIP-51® Interlaminar Fusion System for minimally invasive L5/S1 fusion

Aurora Spine's executives emphasize the transformative nature of their products, particularly highlighting the DEXA-C implant line as the world's first patient-matched interbody implant system.

Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) announces a recorded ZOOM call on September 13, 2024, featuring CEO Trent Northcutt and Alpha Wolf Trading CEO Tim Weintraut. The call will highlight Aurora's latest innovations and financial success, including:

1. DEXA™ Technology: Patient-specific interbody implants
2. New Product Launches: Hydra and Osteo-Onyx Lumbar Screw Systems
3. ZIP™ Multi-Center Study Results
4. SiLO™ TFX SI Joint Fusion System: Fastest-growing product

Financial highlights include:
- Q2 2024 EBITDAC: $105,522
- Q2 2024 sales: $4,079,543 (14.3% increase)
- Q2 gross margin: 62.4%
- SiLO™ sales: $1.7 million (41.7% of Q2 revenue)
- ZIP™ 51 sales doubled to $669,316

Aurora continues to expand its sales force and host advanced training sessions for physicians.

Aurora Spine (TSXV: ASG) (OTCQB: ASAPF) has announced its participation in the Latin America Pain Society (LAPS) Annual Congress from September 5-7, 2024, in Mexico City. The company, which specializes in designing and manufacturing innovative medical devices for spinal surgery, will showcase its latest advancements in minimally invasive spinal devices and pain management solutions.

The LAPS conference provides Aurora Spine with a platform to present technologies aimed at optimizing patient care, reducing recovery times, and improving quality of life. The event brings together nationally and internationally renowned experts in pain management, offering opportunities for knowledge sharing and peer interaction. Matt Goldstone, Chief Commercial Officer of Aurora Spine, expressed excitement about participating in the conference and showcasing the company's cutting-edge advances and state-of-the-art technologies for better patient care.

Aurora Spine (OTCQB: ASAPF), a developer of innovative spinal surgery devices, will participate in the Sixth Annual American Society of Pain & Neuroscience (ASPN) Conference from July 11-14, 2024, in Miami Beach, Florida. Aurora will showcase its products at Booth 121 and host a product theater on July 12th at 10:15 a.m.

During the event, prominent physicians Dr. Pankaj Mehta, Dr. Steven Falowski, and Dr. Jason Pope will present findings from Aurora Spine’s Refine Study. This study is the first multi-center, multi-specialty, randomized control trial focusing on interlaminar fusion, comparing Aurora’s SILO TFX and ZIP 51 devices. Aurora's President and CEO, Trent Northcutt, expressed enthusiasm for the opportunity to present their cutting-edge products and clinical results to leading physicians.

Aurora Spine has scheduled a conference call to update investors and discuss its first quarter fiscal 2024 financial results. The call will take place on May 14, 2024, at 11:00 a.m. Eastern Time. Interested parties can access the call via dial-in or webcast. A replay will be available for a time.

Aurora Spine marks the completion of the second year of implantation of the world's first patient-bone-density matched interbody device, the DEXA-C. The innovative cervical interbody implants offer personalized solutions for anterior cervical discectomy with fusion procedures, revolutionizing spine surgery. Aurora also received IRB approval for a multicenter study of its DEXA-C Cervical Interbody System and obtained a new US patent for its DEXA Technology, paving the way for further advancements in orthopedic implants.

Aurora Spine Corporation announces the issuance of its second United States Patent for DEXA Technology™ Patient-Matched Implant Technology. The DEXA Technology™ matches a patient’s bone density, promoting bone in-growth while maintaining the biomechanical structure and bone support. The company's DEXA Technology™ is part of its advanced portfolio representing the future of Spinal and Orthopedic implants. The technology has received the prestigious 2022 Best New Spine Technology Award and is well accepted by physicians. The patent strengthens the Company’s intellectual property portfolio significantly, allowing for the creation of implants that match the patient’s specific bone density based on a DEXA Scan/T-score. The technology is designed to overcome common osteoporosis challenges faced in traditional procedures, ultimately improving patient fusion rates and overall clinical outcomes.

Aurora Spine Corporation has announced the issuance of its United States Patent No: 11,832,853 entitled 'Hybrid Radiolucent Surgical Operating Tube'. The patent is for the Ghost Tube™, a translucent thermoplastic body with non-slipping titanium anchors designed to support surgical preparation tools without blocking x-ray visualization during surgery. This patent supports the recently launched SiLO TFX SI Fusion System and will allow the company to create new radiolucent tools for future product lines. Aurora Spine aims to continue being disruptive and innovative in delivering products and improving treatment options for better patient care and outcomes.